Info

MSM Protein Technologies is an emerging biotechnology company with proprietary technologies for generating, selecting, and optimizing human antibodies that precisely and comprehensively target multi-spanning membrane proteins ("multi-spanners"). Multi-spanners play a crucial role in cellular functions and in a large number of important human diseases: Some are targets for a number of small molecule drugs on the market today, while others have proven to be difficult for current drug discovery methods. The company believes that its proprietary drug discovery methodology will make it possible to identify and select antibodies for hundreds different multi-spanners. Antibody drugs that bind to these targets more precisely and comprehensively would offer significant benefits over existing therapies including many blockbuster small molecules drugs now in use. To date, however, handling multi-spanners for selection of such targeting compounds has been problematic. The Company's earlier proprietary methodology was reduced to practice and documented by the founder and colleagues at the Dana-Farber Cancer Institute, a Harvard University teaching affiliate. The Company has developed a sophisticated methodology and a suite of proprietary tools for handling purified multi-spanners in their native state. This advancement opens a substantial opportunity to generate new classes of antibody-based drugs to treat conditions including cancers, cardiovascular, auto-immune, inflammatory, neurodegenerative, and infectious diseases, and pain management, etc., that currently represent major unmet medical needs. Furthermore, MSM scientists have developed a novel proprietary platform technology - the Lesik/Golik platform. The platform is superior to the earlier methodology and offers much higher likelihood of the discovery of functional antibodies - those that can affect a function of a multi-spanner. The Company's fully integrated approach allows for rapid and reliable generation of antibodies targeting multi-spanners for a suite of disease targets previously deemed unreachable by conventional drug discovery methods. To date, antibodies against eleven targets have been generated. Among our competitive advantages are: reduced costs; substantially greater likelihood of success in antibody generation; much faster selection of the antibodies; shorter lead times to drug candidates (including small molecules) and to other products for biomedical research and clinical diagnostics; and broad applicability for targets that are unreachable to others and in many fields including stem cells and proteomics. The Company believes its expertise in multi-spanners makes it unique among other antibody engineering companies.